<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907072</url>
  </required_header>
  <id_info>
    <org_study_id>WVE-DMDX51-003</org_study_id>
    <nct_id>NCT03907072</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy</brief_title>
  <acronym>DYSTANCE 51</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wave Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wave Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an&#xD;
      open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in&#xD;
      ambulatory male pediatric patients with Duchenne muscular dystrophy (DMD) amenable to exon 51&#xD;
      skipping intervention (DYSTANCE 51)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Dystrophin Level (% Normal Dystrophin)</measure>
    <time_frame>Day 1 to Week 12, Week 22, or Week 46</time_frame>
    <description>US/other regions (as applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Day 1 through Week 48</time_frame>
    <description>European Union (EU)/other regions (as applicable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Day 1 through Week 48</time_frame>
    <description>US/other regions (as applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dystrophin Level (% Normal Dystrophin)</measure>
    <time_frame>Day 1 to Week 12, Week 22, or Week 46</time_frame>
    <description>European Union (EU)/other regions (as applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Upper Limb Proximal Strength</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 4-stair Climb</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 10-meter Walk/Run Test</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 95th Percentile of Stride Velocity</measure>
    <time_frame>Day 1 through Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NSAA</measure>
    <time_frame>Day 1 through Week 96</time_frame>
    <description>Long-term evaluation, open label from Week 48 through Week 96</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>WVE-210201 (3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly IV administrations of WVE-210210 at 3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WVE-210201 (4.5 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly IV administrations of WVE-210210 at 4.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WVE-210201 (suvodirsen)</intervention_name>
    <description>WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
    <arm_group_label>WVE-210201 (3 mg/kg)</arm_group_label>
    <arm_group_label>WVE-210201 (4.5 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Buffered saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase&#xD;
&#xD;
          2. Documented mutation in the Dystrophin gene associated with DMD that is amenable to&#xD;
             exon 51 skipping&#xD;
&#xD;
          3. Ambulatory male, able to walk independently for at least 10 meters in 10 seconds or&#xD;
             less at the time of Screening visit (performed as part of the NSAA)&#xD;
&#xD;
          4. Stable pulmonary and cardiac function, as measured by:&#xD;
&#xD;
               1. Reproducible percent predicted forced vital capacity (FVC) ≥50%&#xD;
&#xD;
               2. Left ventricular ejection fraction (LVEF) &gt;55% in patients &lt;10 years of age and&#xD;
                  &gt;45% in patients ≥10 years of age, as measured (and documented) by echocardiogram&#xD;
&#xD;
          5. Currently on a stable corticosteroid therapy regimen, defined as initiation of&#xD;
             systemic corticosteroid therapy occurred ≥6 months prior to Screening, and no changes&#xD;
             in dosing ≤3 months prior to Screening visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiac insufficiency:&#xD;
&#xD;
               1. Severe cardiomyopathy that, in the opinion of the Investigator, prohibits&#xD;
                  participation in this study; however, cardiomyopathy that is managed by&#xD;
                  angiotensin-converting-enzyme (ACE) inhibitors or beta blockers is acceptable&#xD;
                  provided the patient meets the LVEF inclusion criterion&#xD;
&#xD;
               2. Any other evidence of clinically significant structural or functional heart&#xD;
                  abnormality&#xD;
&#xD;
               3. A cardiac troponin I value &gt; 0.2 ng/mL&#xD;
&#xD;
          2. Need for daytime mechanical or non-invasive ventilation OR anticipated need for&#xD;
             daytime mechanical or non-invasive ventilation within the next year, in the opinion of&#xD;
             the Investigator. Nighttime non-invasive ventilation is permitted&#xD;
&#xD;
          3. Received prior treatment with drisapersen or with an investigational&#xD;
             peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)&#xD;
&#xD;
          4. Received prior treatment with gene therapy for DMD&#xD;
&#xD;
          5. Received treatment with ataluren or eteplirsen within the 14 weeks prior to the&#xD;
             planned Baseline biopsy collection&#xD;
&#xD;
          6. Received any investigational drug within 3 months or 5 half-lives, whichever is&#xD;
             longer, prior to the planned Baseline biopsy collection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Panzara, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Wave Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Armand Trosseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C di Neurologia e Malattie Neuromuscolari Centro Clinico Nemo Sud</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Reffaele Via Olgettina, 60</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>8, 00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn Och Ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>41650</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <results_first_submitted>April 5, 2021</results_first_submitted>
  <results_first_submitted_qc>April 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2021</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03907072/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>WVE-210201 (3 mg/kg)</title>
          <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
        </group>
        <group group_id="P2">
          <title>WVE-210201 (4.5 mg/kg)</title>
          <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo: Buffered saline solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>WVE-210201 (3 mg/kg)</title>
          <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
        </group>
        <group group_id="B2">
          <title>WVE-210201 (4.5 mg/kg)</title>
          <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo: Buffered saline solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="B2" value="9" lower_limit="8" upper_limit="10"/>
                    <measurement group_id="B3" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="B4" value="7.5" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Dystrophin Level (% Normal Dystrophin)</title>
        <description>US/other regions (as applicable)</description>
        <time_frame>Day 1 to Week 12, Week 22, or Week 46</time_frame>
        <population>No statistical analysis has been performed due to early study termination</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dystrophin Level (% Normal Dystrophin)</title>
          <description>US/other regions (as applicable)</description>
          <population>No statistical analysis has been performed due to early study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in North Star Ambulatory Assessment (NSAA)</title>
        <description>European Union (EU)/other regions (as applicable)</description>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in North Star Ambulatory Assessment (NSAA)</title>
          <description>European Union (EU)/other regions (as applicable)</description>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in North Star Ambulatory Assessment (NSAA)</title>
        <description>US/other regions (as applicable)</description>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in North Star Ambulatory Assessment (NSAA)</title>
          <description>US/other regions (as applicable)</description>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dystrophin Level (% Normal Dystrophin)</title>
        <description>European Union (EU)/other regions (as applicable)</description>
        <time_frame>Day 1 to Week 12, Week 22, or Week 46</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dystrophin Level (% Normal Dystrophin)</title>
          <description>European Union (EU)/other regions (as applicable)</description>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Upper Limb Proximal Strength</title>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Upper Limb Proximal Strength</title>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 4-stair Climb</title>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 4-stair Climb</title>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 10-meter Walk/Run Test</title>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 10-meter Walk/Run Test</title>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity</title>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity</title>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 95th Percentile of Stride Velocity</title>
        <time_frame>Day 1 through Week 48</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 95th Percentile of Stride Velocity</title>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NSAA</title>
        <description>Long-term evaluation, open label from Week 48 through Week 96</description>
        <time_frame>Day 1 through Week 96</time_frame>
        <population>No statistical analysis has been performed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>WVE-210201 (3 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O2">
            <title>WVE-210201 (4.5 mg/kg)</title>
            <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: Buffered saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NSAA</title>
          <description>Long-term evaluation, open label from Week 48 through Week 96</description>
          <population>No statistical analysis has been performed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study enrollment through early study termination by Sponsor (maximum of 11 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>WVE-210201 (3 mg/kg)</title>
          <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
        </group>
        <group group_id="E2">
          <title>WVE-210201 (4.5 mg/kg)</title>
          <description>WVE-210201 (suvodirsen): WVE-210201 is a stereopure antisense oligonucleotide (ASO)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: Buffered saline solution</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>WAVE Life Sciences</organization>
      <phone>855-215-4687</phone>
      <email>clinicaltrials@wavelifesci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

